Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Hugues de Lavallade"'
Autor:
Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Soledad Undurraga, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James Mccloskey, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane Apperley
Publikováno v:
HemaSphere, Vol 7, p e85501cf (2023)
Externí odkaz:
https://doaj.org/article/f0b8d7a160ec4ce1b84d936813ace846
Autor:
Patrick Harrington, Katie J. Doores, Jamie Saunders, Marc de Lord, Chandan Saha, Thomas Lechmere, Hataf Khan, Ho Pui Jeff Lam, Amy O’ Reilly, Claire Woodley, Susan Asirvatham, Richard Dillon, Natalia Curto-Garcia, Jennifer O’ Sullivan, Shahram Kordasti, Kavita Raj, Michael H. Malim, Deepti Radia, Donal McLornan, Claire Harrison, Hugues de Lavallade
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/8d141df5a2af44408d61b05902336c10
Autor:
Patrick Harrington, Richard Dillon, Deepti Radia, Philippe Rousselot, Donal P. McLornan, Mark Ong, Anna Green, Alessandro Verde, Farzana Hussain, Kavita Raj, Shahram Kordasti, Claire Harrison, Hugues de Lavallade
Publikováno v:
Haematologica, Vol 108, Iss 6 (2023)
Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling. Dasatinib, initially developed as an immunosuppressive agent, is by contrast, also noted to result in enhanced t
Externí odkaz:
https://doaj.org/article/4311aefbb9da4c69beada3dd4677919f
Autor:
Vipul Sheth, Victoria Potter, Hugues de Lavallade, Shreyans Gandhi, Austin Kulasekararaj, Pramila Krishnamurthy, Varun Mehra, Francesco Dazzi, Ghulam Mufti, Antonio Pagliuca, Donal Mclornan, Kavita Raj
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-6 (2021)
Abstract Pre-emptive DLI (pDLI) is an effective strategy in lowering the risk of relapse without significantly increasing the risk of graft-versus-host disease (GVHD) in the case of T cell lineage mixed chimerism (MC) post allogeneic transplant in he
Externí odkaz:
https://doaj.org/article/6a6208a955b94bbda77e11e80c805e95
Autor:
Jamie Saunders, Natalia Curto-Garcia, Priya Sriskandarajah, Jennifer O’Sullivan, Claire Woodley, Susan Asirvatham, Marion Campbell-Drew, Jonathan Mathias, Tim Ellis, Nona Baker, Deepti H. Radia, Sahra Ali, Shahram Kordasti, Patrick Harrington, Hugues de Lavallade, Donal P. McLornan, Claire N. Harrison
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e609 (2021)
Externí odkaz:
https://doaj.org/article/35ea45023d78488a8677879e2168635a
Autor:
Alesia Khan, Claire Woodley, Deepti Radia, George N. Mikhaeel, Jessica Brady, Natalia Curto Garcia, Patrick Harrington, Jennifer O’Sullivan, Shahram Kordasti, Yvonne Francis, Susan Asirvatham, Sahra Ali, Priya Sriskandarajah, Jamie Saunders, Hugues de Lavallade, Donal P. McLornan, Claire N. Harrison
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e611 (2021)
Externí odkaz:
https://doaj.org/article/9bf13ba33ca94e558c21db22cc1d45ba
Autor:
Bruno Fattizzo, Austin G. Kulasekararaj, Anita Hill, Nana Benson-Quarm, Morag Griffin, Talha Munir, Louise Arnold, Kathryn Riley, Robin Ireland, Hugues De Lavallade, Victoria Potter, Dario Consonni, Peter Hillmen, Ghulam J. Mufti, Wilma Barcellini, Judith C. W. Marsh
Publikováno v:
Haematologica, Vol 104, Iss 11 (2019)
Externí odkaz:
https://doaj.org/article/afbb1a7b67a04e4691e516000cf260fe
Publikováno v:
European Medical Journal Hematology, Vol 5, Iss 1, Pp 53-61 (2017)
This symposium was dedicated to discussing BCR-ABL-positive chronic myeloid leukaemia (CML) and Philadelphia-positive acute lymphoblastic leukaemia (Ph+ALL). Prof Baccarani opened the symposium, highlighting the recent improvements in survival in pat
Externí odkaz:
https://doaj.org/article/57dc87f5c13743e0bab6f7a80a4378b8
Autor:
Hugues de Lavallade, Aytug Kizilors
Publikováno v:
European Medical Journal Oncology, Vol 4, Iss 1, Pp 86-95 (2016)
Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have become the standard therapy for chronic myeloid leukaemia (CML). While allogeneic hematopoietic stem cell transplant is a recognised curative treatment for CML
Externí odkaz:
https://doaj.org/article/7f14c9d406f54e688bd967a1fd93adb8
Autor:
Vipul Sheth, Vanessa Kennedy, Hugues de Lavallade, Donal Mclornan, Victoria Potter, Brian G. Engelhardt, Bipin Savani, Wichai Chinratanalab, Stacey Goodman, John Greer, Adetola Kassim, Sally York, Michelle Kenyon, Shreyans Gandhi, Austin Kulasekararaj, Judith Marsh, Ghulam Mufti, Antonio Pagliuca, Madan Jagasia, Kavita Raj
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Dosing regimens for antithymocyte globulin (ATG) and anti-CD52 antibody (alemtuzumab) for graft vs. host disease prophylaxis (GVHD) are empiric or weight-based, and do not account for individual patient factors. Recently, it has been shown that recip
Externí odkaz:
https://doaj.org/article/308eff52f2cd424692d7bd9dc3b203f6